EIKN (NASDAQ:EIKN) Now Covered by JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of EIKN (NASDAQ:EIKN) in a research note issued on Monday,Benzinga reports. The brokerage set an “overweight” rating and a $29.00 price target on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 110.45% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Morgan Stanley initiated coverage on shares of EIKN in a report on Monday. They set an “overweight” rating and a $32.00 price target on the stock. Wall Street Zen raised EIKN to a “hold” rating in a research report on Monday, February 16th. Mizuho initiated coverage on EIKN in a research report on Monday. They issued an “outperform” rating and a $26.00 target price for the company. Wedbush initiated coverage on shares of EIKN in a research note on Thursday. They issued an “underperform” rating and a $7.00 target price on the stock. Finally, Bank of America started coverage on EIKN in a research note on Monday. They issued a “buy” rating and a $34.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $25.60.

EIKN Price Performance

Shares of NASDAQ:EIKN opened at $13.78 on Monday. EIKN has a fifty-two week low of $13.28 and a fifty-two week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.